Michael R Zile Selected Research

sacubitril and valsartan sodium hydrate drug combination

1/2022	Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF.
8/2021	Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE.
1/2021	Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction.
1/2021	Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial.
1/2021	Acute pulmonary pressure change after transition to sacubitril/valsartan in patients with heart failure reduced ejection fraction.
1/2021	Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF.
11/2020	Serum potassium in the PARADIGM-HF trial.
11/2020	Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF.
1/2020	Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction.
1/2020	Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael R Zile Research Topics

Disease

160	Heart Failure 01/2022 - 01/2003
15	Myocardial Infarction 01/2022 - 01/2003
15	Fibrosis (Cirrhosis) 01/2021 - 06/2007
15	Hypertrophy 01/2016 - 09/2003
13	Hypertension (High Blood Pressure) 01/2021 - 05/2006
12	Cardiomyopathies (Cardiomyopathy) 01/2022 - 06/2012
9	Heart Diseases (Heart Disease) 01/2022 - 05/2006
9	Diastolic Heart Failure 06/2015 - 04/2005
8	Atrial Fibrillation 01/2022 - 07/2014
8	Sudden Death 01/2022 - 09/2011
7	Cardiomegaly (Heart Hypertrophy) 01/2016 - 01/2008
6	Hypotension (Low Blood Pressure) 10/2020 - 09/2014
6	Left Ventricular Dysfunction 07/2016 - 08/2006
5	Diabetes Mellitus 01/2020 - 01/2011
5	Cardiovascular Diseases (Cardiovascular Disease) 01/2020 - 05/2006
5	Inflammation (Inflammations) 01/2017 - 04/2015
4	Systolic Heart Failure 01/2021 - 09/2011
4	Stroke (Strokes) 11/2017 - 03/2012
3	Heart Arrest (Cardiac Arrest) 01/2022 - 09/2014
3	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 08/2021 - 05/2011
3	Pulmonary Hypertension 01/2020 - 07/2016
3	Hyperkalemia 10/2019 - 09/2014
3	Coronary Artery Disease (Coronary Atherosclerosis) 09/2018 - 04/2015
3	Necrosis 01/2017 - 12/2005
3	Ventricular Remodeling 01/2013 - 09/2006
3	Ischemia 01/2008 - 12/2005
2	Cardiac Arrhythmias (Arrythmia) 01/2022 - 12/2005
2	Chronic Obstructive Pulmonary Disease (COPD) 12/2021 - 01/2021
2	Bundle-Branch Block (Fascicular Block) 08/2021 - 01/2016
2	Dyspnea (Shortness of Breath) 11/2020 - 10/2019
2	Obesity 10/2020 - 01/2020
2	Angioedema 10/2019 - 09/2014
2	Edema (Dropsy) 10/2019 - 01/2019
2	Proteinuria 01/2019 - 07/2016
2	Cysts 01/2018 - 01/2016

Drug/Important Bio-Agent (IBA)

52	sacubitril and valsartan sodium hydrate drug combinationIBA 01/2022 - 02/2014
37	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2022 - 01/2011
33	Neprilysin (Neutral Endopeptidase)IBA 12/2021 - 09/2013
26	pro-brain natriuretic peptide (1-76)IBA 01/2022 - 05/2011
26	Angiotensin Receptors (Angiotensin II Receptor)IBA 12/2021 - 06/2007
26	Irbesartan FDA LinkGeneric 08/2021 - 02/2008
24	Enalapril FDA LinkGeneric 01/2022 - 07/2014
22	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2021 - 08/2006
18	Biomarkers (Surrogate Marker)IBA 01/2022 - 12/2005
17	Natriuretic PeptidesIBA 11/2021 - 09/2011
13	Matrix Metalloproteinases (MMPs)IBA 09/2014 - 01/2003
12	paragonIBA 01/2022 - 01/2017
12	Mineralocorticoid Receptor AntagonistsIBA 08/2021 - 09/2014
11	CollagenIBA 01/2021 - 05/2011
11	Valsartan (Vals)FDA Link 01/2021 - 06/2007
10	DiureticsIBA 01/2022 - 11/2005
10	Angiotensin Receptor AntagonistsIBA 12/2021 - 06/2007
9	Proteins (Proteins, Gene)FDA Link 01/2021 - 04/2006
7	candesartanIBA 08/2021 - 01/2015
7	Fibrillar CollagensIBA 04/2015 - 01/2009
6	CreatinineIBA 12/2021 - 11/2005
6	aliskiren FDA Link 08/2021 - 10/2017
5	Peptides (Polypeptides)IBA 01/2021 - 06/2008
4	SodiumIBA 12/2021 - 04/2014
4	ConnectinIBA 01/2021 - 04/2015
4	Pharmaceutical PreparationsIBA 01/2019 - 07/2014
4	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 12/2018 - 09/2013
4	Tissue Inhibitor of Metalloproteinase-1IBA 04/2015 - 01/2003
4	Peptide Hydrolases (Proteases)FDA Link 01/2013 - 05/2006
3	Biological ProductsIBA 01/2021 - 01/2013
3	Antihypertensive Agents (Antihypertensives)IBA 01/2021 - 06/2007
3	Cysteine (L-Cysteine)FDA Link 01/2021 - 06/2015
3	PotassiumIBA 01/2021 - 01/2017
3	Sodium Potassium Chloride Symporter Inhibitors (Loop Diuretics)IBA 01/2021 - 01/2019
3	Digoxin (Digitek)FDA LinkGeneric 10/2020 - 08/2006
3	AngiotensinsIBA 10/2019 - 09/2014
3	Troponin T (Troponin T1)IBA 01/2019 - 11/2014
3	Trinitrotoluene (TNT)IBA 01/2019 - 11/2014
3	IntegrinsIBA 01/2012 - 06/2008
3	CalciumIBA 07/2011 - 12/2005
3	CalpainIBA 05/2011 - 07/2008
2	ChloridesIBA 08/2021 - 04/2005
2	Collagen Type III (Type III Collagen)IBA 01/2021 - 09/2011
2	Galectin 3 (LGALS3)IBA 01/2021 - 01/2016
2	Phosphoric Diester Hydrolases (Phosphodiesterases)IBA 01/2021 - 07/2016
2	CytokinesIBA 01/2021 - 01/2020
2	Nitric Oxide (Nitrogen Monoxide)FDA Link 10/2020 - 07/2016
2	praliciguatIBA 10/2020 - 01/2020
2	Insulin (Novolin)FDA Link 01/2019 - 03/2017
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2019 - 01/2008
2	Antisense OligonucleotidesIBA 01/2018 - 01/2016
2	Lisinopril (Prinivil)FDA LinkGeneric 01/2018 - 01/2016
2	AngiotensinogenIBA 01/2018 - 01/2016
2	EnzymesIBA 01/2017 - 09/2007
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 07/2016 - 07/2005
2	Streptozocin (Streptozotocin)FDA Link 04/2016 - 07/2015
2	SphingolipidsIBA 04/2016 - 11/2012
2	CeramidesIBA 04/2016 - 11/2012

Therapy/Procedure

42	Therapeutics 01/2022 - 04/2005
3	Percutaneous Coronary Intervention 04/2015 - 12/2005
2	Cardiac Resynchronization Therapy 01/2022 - 10/2015
2	Implantable Defibrillators (Implantable Cardioverter-Defibrillator) 01/2022 - 01/2017
2	Transplantation 01/2020 - 02/2007
2	Drug Tapering 01/2019 - 01/2017
2	Patient Readmission 01/2016 - 07/2015